Cited by 1,649Epigenetics and DNA MethylationCancer Cells and MetastasisMechanisms of cancer metastasis

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Open access

Kleer, Celina G., Cao, Qi, Varambally, Sooryanarayana, Shen, Ronglai, Ota, Ichiro, Tomlins, Scott A., Ghosh, Debashis, Sewalt, Richard G. A. B., Otte, Arie P., Hayes, Daniel F., Sabel, Michael S., Livant, Donna, Weiss, Stephen J., Rubin, Mark A., Chinnaiyan, Arul M.·2003·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1933744100PMC PMC208805

Open this paper in CoChat — free account

Abstract

The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer. Here we investigate the functional role of EZH2 in cancer cell invasion and breast cancer progression. EZH2 transcript and protein were consistently elevated in invasive breast carcinoma compared with normal breast epithelia. Tissue microarray analysis, which included 917 samples from 280 patients, demonstrated that EZH2 protein levels were strongly associated with breast cancer aggressiveness. Overexpression of EZH2 in immortalized human mammary epithelial cell lines promotes anchorage-independent growth and cell invasion. EZH2-mediated cell invasion required an intact SET domain and histone deacetylase activity. This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1933744100

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Ki67 expression in breast cancer
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Cancer Statistics, 2003
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Self-citation
Diseases of the Breast
Haagenson, C. (1971) · Cited by 1,773

Flagged first, then by citations

Show all 38 references

1 of the 38 references couldn’t be matched to a known paper.

Research works printed but not linked: 7

Ellis M. Hayes D. & Lippman M. (2000) in Diseases of the Breast eds. Harris J. Lippman M. E. & Morrow M. (Lippincott–Raven Philadelpha) pp. 749–798.
Clark G. M. (1996) in Diseases of the Breast eds. Harris. J. L. M.. Morrow M. & Hellman S. (Lippincott–Raven Philadephia) pp. 461–485.
Tie, F., Furuyama, T., Prasad-Sinha, J., Jane, E. & Harte, P. J. (2001) Development (Cambridge, U.K.) 128, 275–286.
Livant, D. L., Linn, S., Markwart, S. & Shuster, J. (1995) Cancer Res. 55, 5085–5093.7585556
Rhodes, D. R., Barrette, T. R., Rubin, M. A., Ghosh, D. & Chinnaiyan, A. M. (2002) Cancer Res. 62, 4427–4433.12154050
Gruvberger, S., Ringner, M., Chen, Y., Panavally, S., Saal, L. H., Borg, A., Ferno, M., Peterson, C. & Meltzer, P. S. (2001) Cancer Res. 61, 5979–5984.11507038
Livant, D. L., Brabec, R. K., Pienta, K. J., Allen, D. L., Kurachi, K., Markwart, S. & Upadhyaya, A. (2000) Cancer Res. 60, 309–320.10667582

Sorted by citations

Items 601–700 of 1,000

Extensive rewiring of epithelial-stromal co-expression networks in breast cancer
Oh, E.-Y., Christensen, S. M., Ghanta, S., Jeong, J. C., Bucur, O., Glass, B., Montaser‐Kouhsari, L., Knoblauch, N., Bertos, N., Saleh, S. M. I., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0675-4 · Cited by 60
Histone Deacetylase Classes I and II Regulate Kaposi's Sarcoma-Associated Herpesvirus Reactivation
Shin, H. J., DeCotiis, J., Giron, M., Palmeri, D., & Lukac, D. M. (2013) · Journal of Virology · doi:10.1128/jvi.02665-13 · Cited by 63
Role of the EZH2 histone methyltransferase as a therapeutic target in cancer
Italiano, A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.05.003 · Cited by 60
Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma
Lv, Y., Yan, G., Meng, G., Zhang, X., & Guo, Q. (2015) · Scientific Reports · doi:10.1038/srep12999 · Cited by 58
Global Levels of H3K27me3 Track with Differentiation in Vivo and Are Deregulated by MYC in Prostate Cancer
Pellakuru, L. G., Iwata, T., Gürel, B., Schultz, D., Hicks, J. L., Bethel, C. R., Yegnasubramanian, S., & Marzo, A. M. D. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.04.021 · Cited by 58
Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer
Hussein, Y. R., Sood, A. K., Bandyopadhyay, S., Albashiti, B., Semaan, A. Y., Nahleh, Z. A., Roh, J., Han, H. D., Lopez‐Berestein, G., & Ali‐Fehmi, R. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.004 · Cited by 60
Inhibition of Enhancer of Zeste Homolog 2 (EZH2) Expression Is Associated With Decreased Tumor Cell Proliferation, Migration, and Invasion in Endometrial Cancer Cell Lines
Eskander, R. N., Ji, T., Huynh, B., Wardeh, R., Randall, L. M., & Hoang, B. H. (2013) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e318296a265 · Cited by 59
Is Glioblastoma an Epigenetic Malignancy?
Maleszewska, M., & Kaminska, B. (2013) · Cancers · doi:10.3390/cancers5031120 · Cited by 63
High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer
Chen, X., Song, N., Matsumoto, K., Nanashima, A., Nagayasu, T., Hayashi, T., Ying, M., Endo, D., Wu, Z., & Koji, T. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2062 · Cited by 62
Overexpression of CDCA7 predicts poor prognosis and induces EZH2‐mediated progression of triple‐negative breast cancer
Ye, L., Li, F., Song, Y., Yu, D., Xiong, Z., Li, Y., Shi, T., Yuan, Z., Lin, C., Wu, X., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31766 · Cited by 57
Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression
Pang, J. C., Toy, K. A., Griffith, K. A., Awuah, B., Quayson, S. E., Newman, L. A., & Kleer, C. G. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2055-z · Cited by 57
Self-citation
PRC2/EED-EZH2 Complex Is Up-Regulated in Breast Cancer Lymph Node Metastasis Compared to Primary Tumor and Correlates with Tumor Proliferation In Situ
Yu, H., Simons, D. L., Segall, I., Cárcamo‐Cavazos, V., Schwartz, E., Yan, N., Zuckerman, N. S., Dirbas, F. M., Johnson, D. L., Holmes, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051239 · Cited by 59
The Role of microRNAs in the Regulation of Apoptosis in Lung Cancer and Its Application in Cancer Treatment
Othman, N., & Nagoor, N. H. (2014) · BioMed Research International · doi:10.1155/2014/318030 · Cited by 57
The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2
Li, Z., Xu, L., Tang, N., Xu, Y., Ye, X., Shen, S., Niu, X., Lü, S., & Chen, Z. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.05.057 · Cited by 58
Dysregulation of the Repressive H3K27 Trimethylation Mark in Head and Neck Squamous Cell Carcinoma Contributes to Dysregulated Squamous Differentiation
Gannon, O. M., de Long, L. M., Endo‐Munoz, L., Hazar-Rethinam, M. H., & Saunders, N. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2505 · Cited by 58
The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
Wong, M., Polly, P., & Liu, T. (2015) · Europe PMC (PubMed Central) · Cited by 57
The epigenetics of tumour initiation: cancer stem cells and their chromatin
Avgustinova, A., & Benitah, S. A. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.01.003 · Cited by 58
Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro
Shen, J. K., Cote, G. M., Gao, Y., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2016) · Scientific Reports · doi:10.1038/srep25239 · Cited by 59
Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity
Das, P., & Taube, J. H. (2020) · Cancers · doi:10.3390/cancers12102792 · Cited by 61
Aberrant Gene Silencing in Tumor Progression: Implications for Control of CancerPreprint
Baylin, S. B., & Chen, W. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.010 · Cited by 58
Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients
Song, Q., Shi, Z., Zhang, Y., Ji, L., Wang, K., Duan, D., & Dang, X. (2014) · Oncology Reports · doi:10.3892/or.2014.2989 · Cited by 56
Targeting EZH2 as cancer therapy
Hanaki, S., & Shimada, M. (2021) · The Journal of Biochemistry · doi:10.1093/jb/mvab007 · Cited by 56
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma
Zhou, J., Roh, J., Bandyopadhyay, S., Chen, Z., Munkarah, A. R., Hussein, Y. R., Alosh, B., Jazaerly, T., Hayek, K., Semaan, A. Y., et al. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.07.128 · Cited by 56
PRC2 during vertebrate organogenesis: A complex in transition
Aldiri, I., & Vetter, M. L. (2012) · Developmental Biology · doi:10.1016/j.ydbio.2012.04.030 · Cited by 59
Lipocalin 2 expression is associated with aggressive features of endometrial cancer
Mannelqvist, M., Stefansson, I. M., Wik, E., Kusonmano, K., Raeder, M. B., Oyan, A. M., Kalland, K., Moses, M. A., Salvesen, H. B., & Akslen, L. A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-169 · Cited by 56
Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder
Wang, H., Albadine, R., Magheli, A., Guzzo, T. J., Ball, M. W., Hinz, S., Schoenberg, M., Netto, G. J., & Gonzalgo, M. L. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.09.005 · Cited by 58
Chromatin modifications remodel cardiac gene expression
Mathiyalagan, P., Keating, S. T., Du, X., & El‐Osta, A. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu122 · Cited by 58
Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis
Wang, X., Zhao, H., Lv, L., Bao, L., Wang, X., & Han, S. (2016) · Scientific Reports · doi:10.1038/srep19239 · Cited by 56
Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma
Hashizume, R. (2017) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2017-0018 · Cited by 59
Chapter 4 Histone Demethylases and Cancer
Kampranis, S. C., & Tsichlis, P. N. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)02004-1 · Cited by 56
SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis
Liu, C., Shi, X., Wang, L., Wu, Y., Jin, F., Bai, C., & Song, Y. (2014) · Tumor Biology · doi:10.1007/s13277-014-1804-5 · Cited by 57
Epigenetic Regulation in Estrogen Receptor Positive Breast Cancer—Role in Treatment Response
Pathiraja, T. N., Stearns, V., & Oesterreich, S. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9166-0 · Cited by 58
EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression
Drelon, C., Berthon, A. S., Mathieu, M., Ragazzon, B., Kuick, R. D., Tabbal, H., Septier, A., Rodriguez, S., Batisse‐Lignier, M., Sahut‐Barnola, I., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw136 · Cited by 59
α-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis
Witkiewicz, A. K., Varambally, S., Shen, R., Mehra, R., Sabel, M. S., Ghosh, D., Chinnaiyan, A. M., Rubin, M. A., & Kleer, C. G. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0607 · Cited by 55
Self-citation
Epigenetic regulation in RCC: opportunities for therapeutic intervention?
Larkin, J., Goh, X. Y., Vetter, M. H. F., Pickering, L. M., & Swanton, C. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2011.236 · Cited by 57
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters
Melling, N., Thomsen, E., Tsourlakis, M. C., Kluth, M., Hube‐Magg, C., Minner, S. J. P., Koop, C., Graefen, M., Hans Heinzer, A., Wittmer, C., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv137 · Cited by 57
Genomic Approaches That Aid in the Identification of Transcription Factor Target Genes
Kirmizis, A., & Farnham, P. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422900803 · Cited by 54
Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis
Curry, E. W., Zeller, C., Masrour, N., Patten, D. K., Gallon, J., Wilhelm-Benartzi, C. S., Ghaem‐Maghami, S., Bowtell, D. D. L., & Brown, R. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1650 · Cited by 54
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer
Reijm, E. A., Jansen, M. P. H. M., Ruigrok-Ritstier, K., van Staveren, I. L., Look, M. P., van Gelder, M. E. M. , Sieuwerts, A. M., Sleijfer, S., Foekens, J. A., & Berns, E. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0836-9 · Cited by 53
ASXL2 promotes proliferation of breast cancer cells by linking ERα to histone methylation
Park, U.-H., Kang, M.-R., Kim, E.-J., Kwon, Y.-S., Hur, W., Yoon, S. K., Song, B.-J., Park, J. H., Hwang, J.-T., Jeong, J.-C., et al. (2015) · Oncogene · doi:10.1038/onc.2015.443 · Cited by 53
Obesity-Associated Alterations in Inflammation, Epigenetics, and Mammary Tumor Growth Persist in Formerly Obese Mice
Rossi, E. L., de Angel, R. E., Bowers, L. W., Khatib, S. A., Smith, L. A., Buren, E. C. V., Bhardwaj, P., Giri, D. D., Estecio, M. R., Troester, M. A., et al. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0348 · Cited by 53
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4
Breslin, S., Lowry, M. C., & O’Driscoll, L. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.445 · Cited by 53
EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis
Moore, H. M., Gonzalez, M. E., Toy, K. A., Cimino‐Mathews, A., Argani, P., & Kleer, C. G. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2498-x · Cited by 55
Self-citation
PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins
Zoabi, M., Sadeh, R., de Bie, P., & Ciechanover, A. J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.025 · Cited by 54
The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells
Sakurai, T., Bilim, V. N., Ugolkov, A. V., Yuuki, K., Tsukigi, M., Motoyama, T., & Tomita, Y. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.035 · Cited by 54
Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
Ott, M., Litzenburger, U. M., Sahm, F., Rauschenbach, K. J., Tudoran, R., Hartmann, C. J., Márquez, V. E., von Deimling, A., Wick, W., & Platten, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047663 · Cited by 55
Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation
Momparler, R. L., Idaghdour, Y., Márquez, V. E., & Momparler, L. F. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.03.001 · Cited by 54
Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells
Bapat, S. A., Jin, V. X., Berry, N. B., Balch, C., Sharma, N., Kurrey, N. K., Zhang, S., Fang, F., Lan, X., Li, M., et al. (2010) · Epigenetics · doi:10.4161/epi.5.8.13014 · Cited by 55
High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer
Reijm, E. A., Timmermans, A. M., Look, M. P., Gelder, M. E. M., Stobbe, C., van Deurzen, C. H. M., Martens, J. W. M., Sleijfer, S., Foekens, J. A., Berns, P. M. J. J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu391 · Cited by 53
Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing
Jiang, F., He, Y., Wang, H. H., Zhang, H., Zhang, J., Yan, X., Wang, X.-J., Che, Q., Ke, J., Chen, Z., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6350 · Cited by 52
Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling
Song, H., Yu, Z., Sun, X., Feng, J. L., Qi, Y., Khan, H., Zhu, X., Huang, L., Li, M., Mok, M. T. S., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.043 · Cited by 52
Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer
Choi, J. H., SONG, Y. S., Yoon, J. S., Song, K. W., & Lee, Y. Y. (2010) · Apmis · doi:10.1111/j.1600-0463.2009.02579.x · Cited by 52
Acute myeloid leukemia: Therapeutic impact of epigenetic drugs
Altucci, L., Clarke, N., Nebbioso, A., Scognamiglio, A., & Gronemeyer, H. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.04.019 · Cited by 52
Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities
Hu, X., Zhang, J., Zhang, Y., Jiao, F., Wang, J., Chen, H., Ouyang, L., & Wang, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114094 · Cited by 51
Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer
Chen, H.-M., Gao, S., Li, J., Liu, D., Sheng, C., Yao, C., Jiang, W., Wu, J., Chen, S., & Huang, W. (2015) · Oncotarget · doi:10.18632/oncotarget.3790 · Cited by 51
Epigenetic targets and drug discovery
Liu, Y., Liu, K., Su, Q., Xu, C., & Min, J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.007 · Cited by 51
Ribavirin as a tri-targeted antitumor repositioned drug
la Cruz-Hernández, E. N. D., Medina‐Franco, J. L., Trujillo, J. E., Chávez-Blanco, A. D., Domínguez-Gómez, G., Pérez‐Cárdenas, E., González‐Fierro, A., Taja‐Chayeb, L., & Dueñas‐González, A. (2015) · Oncology Reports · doi:10.3892/or.2015.3816 · Cited by 51
EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor
Hwang, C., Giri, V. N., Wilkinson, J. C., Wright, C. W., Wilkinson, A. S., Cooney, K. A., & Duckett, C. S. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9542-7 · Cited by 51
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis
Mahmoud, F. A., Shields, B. D., Makhoul, I., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1167291 · Cited by 53
Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma
Chen, Y., Lin, M. C. M., Wang, H., Chan, C., Jiang, L., Ngai, S. M., Yu, J. Q., He, M., Shaw, P., Yew, D. T. W., et al. (2007) · PROTEOMICS · doi:10.1002/pmic.200700019 · Cited by 51
YC ‐1 inhibits proliferation of breast cancer cells by down‐regulating EZH 2 expression via activation of c‐ C bl and ERK
Chang, L., Lin, H., Tsai, M., Chou, R., Lee, F., Teng, C., Hsieh, M., Hung, H., Huang, L., Yu, Y., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12708 · Cited by 50
Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma
Liu, D.-C., & Yang, Z. (2011) · Pathology - Research and Practice · doi:10.1016/j.prp.2011.05.010 · Cited by 51
A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity
Bajpe, P. K., Prahallad, A., Horlings, H. M., Nagtegaal, I. D., Beijersbergen, R. L., & Bernards, R. (2014) · Oncogene · doi:10.1038/onc.2013.588 · Cited by 51
A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Ott, H. M., Graves, A. P., Pappalardi, M. B., Huddleston, M. J., Halsey, W. S., Hughes, A. M., Groy, A., Dul, E., Jiang, Y., Bai, Y., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0876 · Cited by 51
Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Yang, Y., Kim, H., Li, W., & Kong, A. T. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150826114359 · Cited by 52
EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis
Liu, H., Li, W., Yu, X., Gao, F., Duan, Z., Ma, X., Tan, S., Yuan, Y., Liu, L., Wang, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10841 · Cited by 50
MUC1-C activates EZH2 expression and function in human cancer cells
Rajabi, H. N., Hiraki, M., Tagde, A., Alam, M., Bouillez, A., Christensen, C. L., Samur, M., Wong, K., & Kufe, D. W. (2017) · Scientific Reports · doi:10.1038/s41598-017-07850-0 · Cited by 50
Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells
Zhao, F., Chen, Y., Linglan, Z., Li, R., Zeng, R., Wen, L., Liu, Y., & Zhang, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.05.034 · Cited by 50
Discovery of genes expressed in Hydra embryogenesis
Genikhovich, G., Kürn, U., Hemmrich, G., & Bosch, T. C. G. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2005.10.028 · Cited by 50
Epigenetic Regulation of Epidermal DifferentiationPreprint
Perdigoto, C. N., Valdés, V. J., Bardot, E., & Ezhkova, E. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015263 · Cited by 50
CR Cistrome: a ChIP-Seq database for chromatin regulators and histone modification linkages in human and mouse
Wang, Q., Huang, J., Sun, H., Liu, J., Wang, J., Wang, Q., Qin, Q., Mei, S., Zhao, C., Yang, X., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1151 · Cited by 49
Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
Fiskus, W. C., Rao, R., Balusu, R., Ganguly, S., Tao, J., Sotomayor, E. M., Mudunuru, U., Smith, J. E., Hembruff, S. L., Atadja, P. W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0873 · Cited by 49
Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer
Wu, C., Jin, X., Yang, H. J., Yang, Y., He, Y., Ding, L., Pan, Y., Chen, S., Jiang, J., & Huang, H. (2015) · Oncotarget · doi:10.18632/oncotarget.6497 · Cited by 49
Histone Demethylation and Toll‐like Receptor 8–Dependent Cross‐Talk in Monocytes Promotes Transdifferentiation of Fibroblasts in Systemic Sclerosis Via Fra‐2
Ciechomska, M., O’Reilly, S., Przyborski, S. A., Oakley, F., Bogunia‐Kubik, K., & van Laar, J. M. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39602 · Cited by 49
The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer
Cabello, P., Pineda, B., Tormo, E., Lluch, A. M., & Eroles, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081298 · Cited by 51
EZH2 inhibitors: a patent review (2014-2016)
Stazi, G., Zwergel, C., Mai, A., & Valente, S. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1316976 · Cited by 49
Epigenomics of mammary gland development
Holliday, H., Baker, L. A., Junankar, S. R., Clark, S. J., & Swarbrick, A. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1031-x · Cited by 52
Drugging histone methyltransferases in cancer
Richart, L., & Margueron, R. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.009 · Cited by 51
An Overview of Privileged Scaffold: Quinolines and Isoquinolines in Medicinal Chemistry as Anticancer Agents
Mao, Y., Soni, K. V., Sangani, C. B., & Yao, Y. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620999200917154225 · Cited by 49
Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer
Anwar, T., Gonzalez, M. E., & Kleer, C. G. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.01.013 · Cited by 50
Self-citation
Histone modifications: Targeting head and neck cancer stem cells
Le, J. M. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i5.511 · Cited by 49
Lysine methyltransferase inhibitors: where we are now
Feoli, A., Viviano, M., Cipriano, A., Milite, C., Castellano, S., & Sbardella, G. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00196e · Cited by 50
Polyploid giant cancer cells, EZH2 and Myc upregulation in mammary epithelial cells infected with high-risk human cytomegalovirus
Nehme, Z., Pasquereau, S., Ahmad, S. H., Baba, R. E., & Herbein, G. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104056 · Cited by 48
Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis
Wang, X., Hu, B., Shen, H., Zhou, H., Xue, X., Chen, Y., Chen, S., Han, Y., Yuan, B., Zhao, H., et al. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.07.038 · Cited by 48
Profiling Cancer Stem Cells in Androgen‐Responsive and Refractory Human Prostate Tumor Cell Lines
Cocciadiferro, L., Miceli, V., Kang, K., Polito, L. M., Trosko, J. E., & Carruba, G. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03696.x · Cited by 48
RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF-κB/Snail/YY1/RKIP Resistance-Driver Loop
Bonavida, B. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014011929 · Cited by 48
Intra-Tumour Signalling Entropy Determines Clinical Outcome in Breast and Lung Cancer
Banerji, C. R. S., Simone Severini, B., Caldas, C., & Teschendorff, A. E. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004115 · Cited by 48
Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells
Nakagawa, S., Sakamoto, Y., OKABE, H., Hayashi, H., Hashimoto, D., Yokoyama, N., Tokunaga, R., Sakamoto, K., Kuroki, H., Mima, K., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2922 · Cited by 48
EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features
Guo, S., Li, X., Rohr, J. M., Wang, Y., Ma, S., Chen, P., & Wang, Z. (2016) · Diagnostic Pathology · doi:10.1186/s13000-016-0491-5 · Cited by 48
Role of steroid receptor and coregulator mutations in hormone-dependent cancers
Groner, A. C., & Brown, M. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88885 · Cited by 49
Bivalent Epigenetic Control of Oncofetal Gene Expression in Cancer
Zaidi, S. K., Frietze, S. E., Gordon, J. A. R., Heath, J. L., Messier, T., Hong, D., Boyd, J. R., Kang, M., Imbalzano, A. N., Lian, J. B., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00352-17 · Cited by 53
The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 (PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity
Pellecchia, S., Sepe, R., Decaussin‐Petrucci, M., Ivan, C., Shimizu, M., Coppola, C., Testa, D., Calin, G. A., Fusco, A., & Pallante, P. (2020) · Cancers · doi:10.3390/cancers12010235 · Cited by 48
Altered Expression of the Early Mitotic Checkpoint Protein, CHFR, in Breast Cancers: Implications for Tumor Suppression
Vinnedge, L. M. P., Gonzalez, M. E., Ding, L., Kleer, C. G., & Petty, E. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4109 · Cited by 48
Self-citation
Enhancer of zeste homolog 2 activates wnt signaling through downregulating CXXC finger protein 4
Lu, H., Sun, J., Wang, F., Feng, L., Ma, Y., Shen, Q., Jiang, Z., Sun, X., Wang, X., & Jin, H. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.293 · Cited by 50
EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation
Mu, W., Starmer, J., Yee, D., & Magnuson, T. (2018) · Epigenetics & Chromatin · doi:10.1186/s13072-018-0242-9 · Cited by 52
Polycomb Group Genes: Keeping Stem Cell Activity in Balance
Sauvageau, M., & Sauvageau, G. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060113 · Cited by 48
EZH2‐mediated SLC7A11 upregulation via miR‐125b‐5p represses ferroptosis of TSCC
Yu, Y., Al‐Sharani, H. M., & Zhang, B. (2021) · Oral Diseases · doi:10.1111/odi.14040 · Cited by 46
Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma
Jia, N., Li, Q., Tao, X., Wang, J., Hua, K., & Feng, W. (2014) · Oncology Letters · doi:10.3892/ol.2014.2437 · Cited by 46
Loss of ZBRK1 Contributes to the Increase of KAP1 and Promotes KAP1-Mediated Metastasis and Invasion in Cervical Cancer
Lin, L.-F., Li, C., Wang, W., Yang, W., Wang, D. D. H., Chang, W., Lee, W., & Wang, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073033 · Cited by 46
Deregulated Expression of the Polycomb-Group Protein SUZ12 Target Genes Characterizes Mantle Cell Lymphoma
Martín-Pérez, D., Sánchez, E., Maestre, L., Suela, J., Vargiu, P., Lisio, L. D., Martı́nez, N., Alves, J., Piris, M. A., & Sánchez‐Beato, M. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090769 · Cited by 46

Authors: Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., Sabel, M. S., Livant, D., Weiss, S. J., Rubin, M. A., & Chinnaiyan, A. M.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Kleer, Celina G.
Cao, Qi
Varambally, Sooryanarayana
Shen, Ronglai
Ota, Ichiro
Tomlins, Scott A.
Hayes, Daniel F.
Sabel, Michael S.
Weiss, Stephen J.
Rubin, Mark A.
Chinnaiyan, Arul M.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2003-09-19
Volume: 100
Issue: 20
Pages: 11606-11611
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1933744100
PMC: PMC208805
OpenAlex: W2100365251
Cited by: 1,649
References: 38
Citations by year: 2026: 21 · 2025: 43 · 2024: 53 · 2023: 72 · 2022: 55 · 2021: 67 · 2020: 94 · 2019: 69 · 2018: 83 · 2017: 91 · 2016: 109 · 2015: 109 · 2014: 116 · 2013: 114 · 2012: 108
FWCI: 12.78
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UvA-DARE (University of Amsterdam) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: National Cancer Institute (P50-CA-69568, R01CA097063, R01 CA97063, P50CA069568)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords: EZH2, Polycomb group proteins, breast cancer aggressiveness, breast cancer progression, cell invasion, anchorage-independent growth, oncogenic transformation, mammary epithelial cells, SET domain, histone deacetylase activity, transcriptional repression, cellular memory, prognostic factors
MeSH terms: Enhancer of Zeste Homolog 2 Protein, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, DNA-Binding Proteins, Epithelial Cells, Female, Humans, Immunohistochemistry, Proteins, RNA, Messenger, Transcription Factors, Polymerase Chain Reaction, Polycomb Repressive Complex 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks